

Erratum

Combining peptide TNIIIA2 with all-*trans* retinoic acid accelerates N-Myc protein degradation and neuronal differentiation in MYCN-amplified neuroblastoma cells: Am J Cancer Res. 2019; 9(2): 434-448

Kazuki Otsuka^{1*}, Manabu Sasada^{1,3,4*}, Takuya Iyoda⁵, Yusuke Nohara¹, Shunsuke Sakai¹, Tatsufumi Asayama¹, Yusuke Suenaga⁴, Sana Yokoi⁴, Yoshikazu Higami^{2,3}, Hiroaki Kodama⁶, Fumio Fukai^{1,3}

*Departments of ¹Molecular Patho-Physiology, ²Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan; ³Translational Research Center, Research Institutes for Science and Technology, Tokyo University of Science, Noda, Chiba, Japan; ⁴Cancer Genome Center, Chiba Cancer Center Research Institute, Chiba, Japan; ⁵Department of Pharmacy, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Sanyo-Onoda, Yamaguchi, Japan; ⁶Department of Biochemistry, Faculty of Science and Engineering, Saga University, Saga, Japan. *Equal contributors.*

Received December 8, 2019; Accepted December 11, 2019; Epub January 1, 2020; Published January 15, 2020

In this article published in AJCR0090684, a mistake has been found that **Figure 6** was wrong: The MG-132 concentration should be 1 μ M in Lane 5 and Lane 7 in **Figure 6B** on page 441. So, we would like to publish this Erratum to reflect this change. The authors express regrets for this mistake.

Address correspondence to: Dr. Fumio Fukai, Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan. Tel: 81-4-7124-1501 Ext. 4645; Fax: 81-4-7121-3608; E-mail: fukai@rs.noda.tus.ac.jp

New strategy for differentiation therapy based on N-Myc degradation




Figure 6. Decrease in N-myc protein level induced by the combination of ATRA with TNIIIA2 is caused by proteasomal degradation.